Back to results
US 2022/0175815 A1Published application
Combination therapies based on pd1 and il-17b inhibitors
AssigneeOrega Biotech
InventorsNathalie BONNEFOY, Jérémy BASTID
Life of this patent
Estimating the term…
Abstract
The present invention concerns the combination of PD1 and IL-17B inhibitors, especially for the treatment of patients and diseases resistant to anti-PD1 therapies.
Claims18
A composition comprising an inhibitor of PD1 or of a ligand thereof and an inhibitor of IL-17B or of a receptor thereof.
A method of treating cancer or an infectious disease in a subject, comprising administering to the subject a composition comprising an inhibitor of IL-17B or of a receptor thereof, wherein the subject has been treated with an inhibitor of PD1 or of a ligand thereof.
Dependencies are inferred from the claim text.